GLP-1 receptor agonist medications (including semaglutide, dulaglutide, liraglutide, exenatide, and lixisenatide) are typically considered for type 2 diabetes when: Triple therapy with other diabetes medications is not effective, not tolerated, or contraindicated The person has a BMI 35 kg/m (adjusted by 2.5 kg/m for people from South Asian, Chinese, other Asian, Black African, or African-Caribbean backgrounds) and specific weight-related psychological or medical problems A lower BMI threshold may be appropriate if weight loss would benefit other obesity-related comorbidities Insulin would not be appropriate or acceptable to the person Treatment is usually continued only if there is a beneficial metabolic response (reduction in HbA1c and weight) after 6 months
3d), suggesting that GLP-1MK-801 engages signalling pathways that are related to both receptor systems in the hypothalamus
10.1016/j.jacep.2024.03.031 138
Aspirin may be considered in the context of high CV risk with low bleeding risk, but generally not in older adults
rskov, Holst, Seier, Poulsen, Kirkegaard)